1. A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (June 2017) Authors: Sauter, C.S.; Matasar, M.J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M.L.; Portlock, C.S.; Straus, D.J.; Zelenetz, A.D.; McCall, S.S.; Miller, S.T.; Courtien, A.I.; Younes, A.; Moskowitz, C.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. (June 2017) Authors: Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P.M.; Batlevi, C.L.; Chen, R.; Constine, L.S.; Courtien, A.I.; Dandapani, S.V.; Drullinsky, P.; Friedberg, J.W.; Hamlin, P.A.; Hoppe, R.T.; Matasar, M.J.; McArthur, G.N.; Miller, S.T.; Moskowitz, A.J.; Noy, A.; Schoder, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP‐LIKE REGIMENS. (12th June 2019) Authors: Rajeeve, S.; Bobillo, S.V.; Zelenetz, A.D.; Straus, D.J.; Palomba, M.L.; Noy, A.; Horwitz, S.M.; Moskowitz, A.J.; Hamlin, P.A.; Matasar, M.J.; Kumar, A.; Batlevi, C.L.; von Keudell, G.; Yahalom, J.; Dogan, A.; Drill, E.; Younes, A.; Joffe, E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 264 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. REAL‐WORLD ASSESSMENT OF PRACTICE EFFICIENCY WITH THE INTRODUCTION OF SUBCUTANEOUS RITUXIMAB. (12th June 2019) Authors: Matasar, M.J.; Qiu, A.; Shapouri, S.; Drill, E.N.; Schade, J.; Ravelo, A.; Ni, A.; To, T.M.; Dawson, K.L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 540 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. (June 2017) Authors: Soumerai, J.D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K.S.; Palomba, M.; Gerecitano, J.F.; Noy, A.; Hamlin, P.; Moskowitz, C.H.; Copeland, A.R.; Matasar, M.J.; Drullinsky, P.R.; Hamilton, A.; Horwitz, S.M.; Intlekofer, A.M.; Kumar, A.; Moskowitz, A.; Portlock, C.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗